Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts
September 29, 2015 15:52 ET
|
Provista Diagnostics, Inc.
NEW YORK, NY, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel...
Provista Diagnostics, Inc. published Late-Breaking Publication only Abstract in conjunction with the 2015 ASCO Annual Meeting
June 03, 2015 15:31 ET
|
Provista Diagnostics, Inc.
NEW YORK, NY, June 3, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that they published
an Abstract, in conjunction with the 2015 ASCO Annual Meeting held
May 29 - June 2th, 2015...
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
June 01, 2015 09:00 ET
|
OncoMed Pharmaceuticals, Inc.
Demcizumab plus Abraxane and Gemcitabine in Advanced Pancreatic Cancer Results in 50% Response Rate, Progression-Free Survival of 9.0 Months and Overall Survival of 10.1 Months
Randomized Phase 2...
Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma
June 01, 2015 09:00 ET
|
Chinook Therapeutics, Inc.
BERKELEY, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of interim safety and efficacy data from an ongoing Phase 1b clinical trial of its...
OncoMed to Present at Upcoming Investment Conferences
May 28, 2015 16:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
OncoMed to Present Data From Three Clinical Studies at the 2014 ASCO Annual Meeting
May 14, 2014 17:02 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
May 30, 2013 07:30 ET
|
Genelux Corporation
SAN DIEGO, CA--(Marketwired - May 30, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today...
Tunstall AMAC Announces Dr. Moriah J. Weissman Accepted as Member of ASCO
May 07, 2012 09:30 ET
|
Tunstall AMAC
NEW YORK, NY--(Marketwire - May 7, 2012) - Tunstall AMAC, a healthcare communication company dedicated to supporting the healthcare community with healthcare communication solutions and advanced...
Semafore Pharmaceuticals to Present SF1126 Clinical Data at ASCO Annual Meeting
May 26, 2011 08:30 ET
|
Semafore Pharmaceuticals
INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of...
Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
May 21, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - May 21, 2010) - Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...